RU2014140119A - Способы повышения эффективности терапии на основе cd37 - Google Patents
Способы повышения эффективности терапии на основе cd37 Download PDFInfo
- Publication number
- RU2014140119A RU2014140119A RU2014140119A RU2014140119A RU2014140119A RU 2014140119 A RU2014140119 A RU 2014140119A RU 2014140119 A RU2014140119 A RU 2014140119A RU 2014140119 A RU2014140119 A RU 2014140119A RU 2014140119 A RU2014140119 A RU 2014140119A
- Authority
- RU
- Russia
- Prior art keywords
- sample
- expression
- antibody
- cancer
- staining
- Prior art date
Links
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 title claims abstract 42
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 title claims abstract 42
- 238000002560 therapeutic procedure Methods 0.000 title claims 2
- 238000000034 method Methods 0.000 claims abstract 46
- 206010028980 Neoplasm Diseases 0.000 claims abstract 31
- 201000011510 cancer Diseases 0.000 claims abstract 29
- 239000000523 sample Substances 0.000 claims abstract 27
- 238000010186 staining Methods 0.000 claims abstract 27
- 239000000463 material Substances 0.000 claims abstract 24
- 210000004027 cell Anatomy 0.000 claims abstract 22
- 229940127121 immunoconjugate Drugs 0.000 claims abstract 17
- 238000003364 immunohistochemistry Methods 0.000 claims abstract 16
- 239000013074 reference sample Substances 0.000 claims abstract 12
- 238000001514 detection method Methods 0.000 claims abstract 11
- 101150066967 CD37 gene Proteins 0.000 claims abstract 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract 3
- 102000004169 proteins and genes Human genes 0.000 claims abstract 3
- 238000011319 anticancer therapy Methods 0.000 claims abstract 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 5
- 101710112752 Cytotoxin Proteins 0.000 claims 4
- -1 N-maleimidopropionamido Chemical group 0.000 claims 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims 4
- 239000002619 cytotoxin Substances 0.000 claims 4
- 201000003444 follicular lymphoma Diseases 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 229930126263 Maytansine Natural products 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 claims 3
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 claims 2
- GTBCXYYVWHFQRS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)pentanoate Chemical group C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CCC1=O GTBCXYYVWHFQRS-UHFFFAOYSA-N 0.000 claims 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 206010003908 B-cell small lymphocytic lymphoma Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims 2
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims 2
- 229960005558 mertansine Drugs 0.000 claims 2
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 claims 2
- 239000013049 sediment Substances 0.000 claims 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- ORKSBKSSOSUJOY-UHFFFAOYSA-N 2,5-dioxo-1-[4-(pyridin-2-yldisulfanyl)pentanoyloxy]pyrrolidine-3-sulfonic acid Chemical compound C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CC(S(O)(=O)=O)C1=O ORKSBKSSOSUJOY-UHFFFAOYSA-N 0.000 claims 1
- XZRIDBDNMXPOMF-UHFFFAOYSA-N 4-[[1-(2,5-dioxopyrrolidin-1-yl)-2H-pyridin-2-yl]disulfanyl]-2-sulfopentanoic acid Chemical compound CC(CC(C(O)=O)S(O)(=O)=O)SSC1C=CC=CN1N1C(=O)CCC1=O XZRIDBDNMXPOMF-UHFFFAOYSA-N 0.000 claims 1
- GWEVSJHKQHAKNW-UHFFFAOYSA-N 4-[[1-(2,5-dioxopyrrolidin-1-yl)-2h-pyridin-2-yl]disulfanyl]-2-sulfobutanoic acid Chemical compound OC(=O)C(S(O)(=O)=O)CCSSC1C=CC=CN1N1C(=O)CCC1=O GWEVSJHKQHAKNW-UHFFFAOYSA-N 0.000 claims 1
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 1
- 229960005532 CC-1065 Drugs 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 1
- 229930195731 calicheamicin Natural products 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 229930188854 dolastatin Natural products 0.000 claims 1
- 229960005501 duocarmycin Drugs 0.000 claims 1
- 229930184221 duocarmycin Natural products 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 claims 1
- YACHGFWEQXFSBS-RJXCBBHPSA-N leptomycin Chemical class OC(=O)/C=C(C)/C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)/C=C(\C)/C=C/C[C@@H](C)\C=C(/CC)\C=C\[C@@H]1OC(=O)C=C[C@@H]1C YACHGFWEQXFSBS-RJXCBBHPSA-N 0.000 claims 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 210000003519 mature b lymphocyte Anatomy 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 claims 1
- 230000003393 splenic effect Effects 0.000 claims 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261618489P | 2012-03-30 | 2012-03-30 | |
| US61/618,489 | 2012-03-30 | ||
| PCT/US2013/034646 WO2013149171A2 (en) | 2012-03-30 | 2013-03-29 | Methods for increasing efficacy of cd37-based therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014140119A true RU2014140119A (ru) | 2016-05-27 |
Family
ID=49261399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014140119A RU2014140119A (ru) | 2012-03-30 | 2013-03-29 | Способы повышения эффективности терапии на основе cd37 |
Country Status (14)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2767693C1 (ru) * | 2021-03-03 | 2022-03-18 | Федеральное государственное бюджетное учреждение науки "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства" | Способ морфометрической оценки прогноза течения диффузной B-крупноклеточной лимфомы по индексу доли опухолевых клеток, экспрессирующих pSTAT3 и pAKT1 в лимфатических узлах |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ602176A (en) | 2010-03-12 | 2015-01-30 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
| EP2694105A4 (en) | 2011-04-01 | 2015-04-29 | Immunogen Inc | CD37 BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF |
| US20150343077A1 (en) * | 2014-05-13 | 2015-12-03 | Immunogen, Inc. | Anti-CD37 Immunoconjugate Dosing Regimens |
| MX392539B (es) | 2015-06-08 | 2025-03-24 | Debiopharm Int Sa | Combinaciones de inmunoconjugado anti-cd37 y anticuerpo anti-cd20. |
| UA129489C2 (uk) * | 2015-08-28 | 2025-05-14 | Дебіофарм Інтернаціонал, С.А. | Антитіло до cd37 |
| US11278629B2 (en) | 2016-11-02 | 2022-03-22 | Debiopharm International, S.A. | Methods for improving anti-CD37 immunoconjugate therapy |
| CN107603276A (zh) * | 2017-09-14 | 2018-01-19 | 郑州乐业生物科技有限公司 | 一种稳定的生物染色剂及其制备方法 |
| CN110511900B (zh) * | 2018-05-21 | 2023-08-04 | 中国科学院分子细胞科学卓越创新中心 | 精子细胞表面标志物的筛选与应用 |
| US12144818B2 (en) | 2018-05-30 | 2024-11-19 | Debiopharm International, S.A. | Method for treating cancer in a human patient by administering an anti-CD37 immunoconjugate using various dosing regimens |
| CN111579798A (zh) * | 2020-05-29 | 2020-08-25 | 深圳市锦欣医疗科技创新中心有限公司 | 一种评估子宫内膜容受性的试剂盒及其使用方法 |
| WO2021241061A1 (ja) * | 2020-05-29 | 2021-12-02 | ソニーグループ株式会社 | 情報処理装置、情報処理方法、コンピュータプログラム、およびターゲット分子検出システム |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8318906B2 (en) * | 2005-04-15 | 2012-11-27 | The Regents Of The University Of California | EMP2 antibodies and their therapeutic uses |
| PE20120259A1 (es) * | 2007-08-09 | 2012-04-04 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| WO2009085573A2 (en) * | 2007-12-28 | 2009-07-09 | Spring Bioscience Corporation | Quality control cell device for immunohistochemistry assay and methods of use thereof |
| RS51975B (sr) * | 2008-04-11 | 2012-02-29 | Emergent Product Development Seattle Llc. | Cd37 imunoterapeutski proizvod i njegova kombinacija sa bifunkcionalnim hemoterapeutskim sredstvom |
| AU2009313877A1 (en) * | 2008-11-13 | 2011-06-30 | Emergent Product Development Seattle, Llc | CD37 immunotherapeutic combination therapies and uses thereof |
| NO331080B1 (no) * | 2010-01-29 | 2011-09-26 | Nordic Nanovector As | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
| NZ602176A (en) * | 2010-03-12 | 2015-01-30 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
| AU2011239583A1 (en) * | 2010-04-15 | 2012-11-29 | Alper Biotech, Llc | Monoclonal antibodies against HER2 antigens, and uses therefor |
-
2013
- 2013-03-29 HK HK15102580.5A patent/HK1202156A1/xx unknown
- 2013-03-29 JP JP2015503652A patent/JP2015514716A/ja not_active Withdrawn
- 2013-03-29 AU AU2013237826A patent/AU2013237826A1/en not_active Abandoned
- 2013-03-29 EP EP13770074.6A patent/EP2831585A4/en not_active Withdrawn
- 2013-03-29 KR KR1020147030199A patent/KR20140143810A/ko not_active Withdrawn
- 2013-03-29 SG SG11201405766SA patent/SG11201405766SA/en unknown
- 2013-03-29 BR BR112014024487A patent/BR112014024487A2/pt not_active IP Right Cessation
- 2013-03-29 WO PCT/US2013/034646 patent/WO2013149171A2/en not_active Ceased
- 2013-03-29 US US14/389,727 patent/US20150093397A1/en not_active Abandoned
- 2013-03-29 RU RU2014140119A patent/RU2014140119A/ru not_active Application Discontinuation
- 2013-03-29 CA CA2868049A patent/CA2868049A1/en not_active Abandoned
- 2013-03-29 CN CN201380018486.5A patent/CN104364651A/zh active Pending
- 2013-03-29 MX MX2014011745A patent/MX2014011745A/es unknown
-
2014
- 2014-09-23 IL IL234813A patent/IL234813A0/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2767693C1 (ru) * | 2021-03-03 | 2022-03-18 | Федеральное государственное бюджетное учреждение науки "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства" | Способ морфометрической оценки прогноза течения диффузной B-крупноклеточной лимфомы по индексу доли опухолевых клеток, экспрессирующих pSTAT3 и pAKT1 в лимфатических узлах |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013237826A1 (en) | 2014-10-09 |
| IL234813A0 (en) | 2014-12-31 |
| EP2831585A2 (en) | 2015-02-04 |
| KR20140143810A (ko) | 2014-12-17 |
| WO2013149171A3 (en) | 2013-11-21 |
| JP2015514716A (ja) | 2015-05-21 |
| MX2014011745A (es) | 2015-01-22 |
| BR112014024487A2 (pt) | 2017-08-08 |
| HK1202156A1 (en) | 2015-09-18 |
| WO2013149171A2 (en) | 2013-10-03 |
| CN104364651A (zh) | 2015-02-18 |
| SG11201405766SA (en) | 2014-10-30 |
| EP2831585A4 (en) | 2015-12-02 |
| CA2868049A1 (en) | 2013-10-03 |
| US20150093397A1 (en) | 2015-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014140119A (ru) | Способы повышения эффективности терапии на основе cd37 | |
| Skidmore et al. | ARX788, a site-specific anti-HER2 antibody–drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1–resistant breast and gastric cancers | |
| HRP20180358T1 (hr) | Postupci povećavanja djelotvornosti terapije raka usmjerene protiv folr1 | |
| JP2015514716A5 (cg-RX-API-DMAC7.html) | ||
| JP2014513068A5 (cg-RX-API-DMAC7.html) | ||
| Ikeda et al. | The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo | |
| Hajji et al. | Arginine deprivation alters microglial polarity and synergizes with radiation to eradicate non-arginine-auxotrophic glioblastoma tumors | |
| Li et al. | Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models | |
| Sherbenou et al. | Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells | |
| Mew et al. | Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation | |
| Robbins et al. | Radiation-induced kidney injury: a role for chronic oxidative stress? | |
| Hayes et al. | Antitumor activity of an anti‐CD 98 antibody | |
| Okada et al. | Local depletion of immune checkpoint ligand CTLA4 expressing cells in tumor beds enhances antitumor host immunity | |
| HRP20170743T1 (hr) | Anti-ceacam5 protutijela i njihova uporaba | |
| HRP20191688T1 (hr) | Cd37-vezujuće molekule i njihovi imunokonjugati | |
| RU2010145942A (ru) | Диагностика и лечение злокачественных опухолей поджелудочной железы, яичников и других злокачественных опухолей | |
| CN102603770A (zh) | 消除肿瘤中的异质或混合细胞群体 | |
| RU2014121820A (ru) | Способ лечения опухолей, устойчивых к анти-egfr терапиям, с помощью конъюгата антитела egfr с цитотоксическим средством | |
| Trédan et al. | The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone | |
| Fromm et al. | Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms | |
| Parihar et al. | Photodynamic treatment of oral squamous cell carcinoma in hamster cheek pouch model using chlorin p6-histamine conjugate. | |
| Yaromina et al. | Overcoming radioresistance with the hypoxia-activated prodrug CP-506: A pre-clinical study of local tumour control probability | |
| Spratt et al. | 89Zr-MSTP2109A, a novel antibody based radiotracer to evaluate and guide the clinical translation of antibody-drug conjugates targeting STEAP1 | |
| Choi et al. | MP01-19 STRUCTURE ESTABLISHMENT OF THREE-DIMENSIONAL (3D) CELL CULTURE PRINTING MODEL FOR BLADDER CANCER | |
| KR20250163875A (ko) | 핵 위치화 폴리펩타이드 및 컨주게이트 및 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180618 |